A Study of BGB-11417 in Participants With Myeloid Malignancies

Prior treatment

• Prior therapy with a B-cell lymphoma-2 inhibitor

Other illness

• History of prior malignancy, with the exception of either a history of MDS or MDS/MPN that has transformed to AML, or other prior malignancy that was treated with a full curative intent and no evidence of recurrence within the past 2 years (eg, localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer)

Other

• A diagnosis of acute promyelocytic leukemia.
• Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
• Known central nervous system involvement by leukemia.
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

• Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:
  • AML, nonacute promyelocytic leukemia
  • MDS
  • MDS/MPN
• Eastern Cooperative Oncology Group performance status of 0 to 2.
• Adequate organ function defined as:
  • Creatinine clearance ≥ 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort)
  • Adequate liver function
• Life expectancy of \> 12 weeks.
• Ability to comply with the requirements of the study.